Evaxion (EVAX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is EVAX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript…

COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and busine…

COPENHAGEN, Denmark, November 18, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will provide a strategy and …

COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial cale…

COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its…

COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data …

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the…

The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting a…

New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing n…

COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud to have been awarded…

Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript…

Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and traded as low as $2.95. Ev…

COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immu…

COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clin…

COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data f…

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the stre…

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Imm…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

